the aid library

Filter

276

Download

View PDF

Medios auxiliares para el diagnóstico microscópico del paludismo

Organización Mundial de la Salud OMS (2010) C_WHO

Medios auxiliares para el diagnóstico microscópico del paludismo.

Download

View PDF

Lineamientos técnicos para el abordaje integral, multidisciplinario e interinstitucional a las personas con pie diabético

José, F.; C G. Alvarenga Cardoza, K.M. Díaz de Naves Ministerio de Salud El Salvador (2021) C1

Technical guidelines for a comprehensive, multidisciplinary and inter-institutional approach to people with diabetic neuropathy

Download

View PDF

Modulo Introductorio

Ministerio de Salud Pública y Bienestar Social Paraguay: Organización Panamericana de la Salud, et al. (2011) C_WHO

Serie de Protocolos de Manejo Clinico para Atencion Primaria de la Salud

Download

View PDF

Chagas Guiá Neuquén

Ministerio de Salud, Argentina (2023) C1

DESDE UN ABORDAJE DE SALUD INTEGRAL Actualización Enero 2023 Neuquén

Download

View PDF

Vigilancia del virus Zika (ZIKV) en las Américas: Detección y diagnóstico por laboratorio

Organización Panamericana de la Salud Organización Mundial de la Salud, Oficina Regional para las Américas (2016) C_WHO

Este algoritmo está dirigido a aquellos laboratorios que cuentan con capacidad instalada para la detección (molecular, antigénica y/o serológica) de dengue (DENV), Zika (ZIKV) y chikungunya(CHIKV),y como parte del diagnóstico diferencial para ... more

Download

View PDF

CORONAVIRUS COVID-19 Manejo Clínico en Pediatría

Faella O. M., Cardozo M. A. et al. Ministerio de Salud Publica Paraguay (2020) C2

CORONAVIRUS COVID-19 Manejo Clínico en Pediatría Paraguay

Download

View PDF

Método madre canguro : guía práctica
recommended

Organización Mundial de la Salud OMS (2003) C_WHO

Los cuidados de la madre canguro son un método de atención a los bebés prematuros. El método consiste en llevar a los bebés, normalmente por la madre, con contacto piel con piel. Esta guía est ... more

Download

View PDF

Articulo 12. El derecho a la Salud

CODEVIDA, Coalición de Organizaciones por el Derecho a la Salud y a la Vida; PROVEA , Programa Venezolano de Educación - Acción en Derechos Humanos (2015) C1

Informe Conjunto de Organizaciones de Defensa del Derecho a la Salud al Comité de Derechos Económicos y Sociales ... more

Download

View PDF

Difteria

Observatorio Venezolano de la Salud (2017) C1

Download

View PDF

Sarampión: una enfermedad re emergente en Venezuela

Ana Carvajal, José Félix Oletta López, Alejandro Rísquez Sociedad Venezolana de Salud Pública (2017) C1

Download

View PDF

Invertir en Salud Mental

Organización Mundial de la Salud OMS (2004) C_WHO

Download

View PDF

Comunicación efectiva para fortalecer la adherencia al tratamiento de las personas afectadas por la tuberculosis. Guía para el facilitador: Personal de Salud

Ministerio de Salud de Peru (2015) CC

La publicación es el resultado de la participación de diversos actores sociales involucrados activamente en la lucha contra la tuberculosis, en el marco ... more

Download

View PDF

Respira Vida. Juntos contra la Tuberculosis

Ministerio de Salud, Peru (2021) CC

PRESENTACIÓN Cada año se registran 220 000 nuevos casos de tuberculosis en la Región de las Américas y mueren más de 50 000 personas a consec ... more

External Link

Poorly Designed PPE a Global Problem forWomen HealthWorkers

Kuehn, B.M. (2022) C1

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more